These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 8261581

  • 21. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM, Reynolds RK, Natale RB.
    Cancer; 1993 Jun 15; 71(12):4060-6. PubMed ID: 8508371
    [Abstract] [Full Text] [Related]

  • 22. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
    Gandara DR, Perez EA, Weibe V, De Gregorio MW.
    Semin Oncol; 1991 Feb 15; 18(1 Suppl 3):49-55. PubMed ID: 1848372
    [Abstract] [Full Text] [Related]

  • 23. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.
    Das B, Antoon R, Tsuchida R, Lotfi S, Morozova O, Farhat W, Malkin D, Koren G, Yeger H, Baruchel S.
    Neoplasia; 2008 Oct 15; 10(10):1105-19. PubMed ID: 18813359
    [Abstract] [Full Text] [Related]

  • 24. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, Piel I, Abeloff MD.
    Cancer; 2001 Nov 15; 92(10):2517-22. PubMed ID: 11745184
    [Abstract] [Full Text] [Related]

  • 25. Neurologic protection by amifostine.
    DiPaola RS, Schuchter L.
    Semin Oncol; 1999 Apr 15; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [Abstract] [Full Text] [Related]

  • 26. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
    Capizzi RL, Oster W.
    Eur J Cancer; 1995 Apr 15; 31A Suppl 1():S8-13. PubMed ID: 7577096
    [Abstract] [Full Text] [Related]

  • 27. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM.
    Semin Oncol; 1998 Oct 15; 25(5):584-99. PubMed ID: 9783598
    [Abstract] [Full Text] [Related]

  • 28. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
    Matsuoka A, Ando Y.
    Gan To Kagaku Ryoho; 2017 Mar 15; 44(3):200-203. PubMed ID: 28292990
    [Abstract] [Full Text] [Related]

  • 29. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W.
    Bone Marrow Transplant; 1997 Nov 15; 20(10):813-9. PubMed ID: 9404920
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    Korst AE, Boven E, van der Sterre ML, Fichtinger-Schepman AM, van der Vijgh WJ.
    Eur J Cancer; 1998 Feb 15; 34(3):412-6. PubMed ID: 9640232
    [Abstract] [Full Text] [Related]

  • 31. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
    Duval M, Daniel SJ.
    J Otolaryngol Head Neck Surg; 2012 Oct 15; 41(5):309-15. PubMed ID: 23092832
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL, Reed E.
    Gynecol Oncol; 1993 Aug 15; 50(2):147-58. PubMed ID: 8375728
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cisplatin nephrotoxicity.
    Fillastre JP, Raguenez-Viotte G.
    Toxicol Lett; 1989 Mar 15; 46(1-3):163-75. PubMed ID: 2650023
    [Abstract] [Full Text] [Related]

  • 38. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT, Ganapathi R, Bukowski RM, Murthy S.
    Eur J Cancer; 1996 Mar 15; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M, Faivre S, Raymond E.
    Drug Saf; 1999 Nov 15; 21(5):367-87. PubMed ID: 10554052
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.